The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.